Complexing amphotericin B (AmB) with lipids or entrapping it in liposomes may increase its efficacy by reducing toxicity and affecting distribution. However, depending on the lipids involved, interference with antifungal activity has been shown. We compared the in vitro activity of AmB colloidal dispersion by cholesteryl sulfate (ABCD) to the standard AmB deoxycholate suspension (ABDS) against 41 isolates of 15 pathogenic species. Broth dilution MIC and minimum fungicidal concentration (MFC) ranges were similar, and the same number of isolates had lower MICs and MFCs with one drug as with the other. Differences between species were noted. In less than a third of comparisons, there were large (fourfold or more) decreases in ABCD activity relative to that of ABDS, and in approximately 1/10, there were large increases. Thus, ABCD complexing variably affects AmB activity. As ABCD pharmacokinetics and toxicology differ from those of ABDS, the significance of these results for in vivo activity needs to be determined.
Amphotericin B (AmB) has been a useful antifungal agent for about 30 years and is the standard against which new drugs are usually measured. However, its well-known toxicities (7) have limited its clinical application. In its present clinical formulation, it is a micellar suspension with sodium deoxycholate (amphotericin B deoxycholate suspension [ABDS]; Fungizone; Bristol-Myers Squibb, Princeton, N.J.). Enveloping AmB in lamellar lipid vesicles (liposomes) has been a promising method of reducing toxicity and altering tissue distribution (11) ; however, such formulations are not easy to prepare or standardize. Lipid complexing of AmB is an attractive alternative for accomplishing the same goals, permitting a preparation that is uniform and reproducible. One such preparation (2) All isolates had been cultured from patients with active disease. The media and methods used for testing each organism were those which had previously been shown in our laboratory to give satisfactory control growth and sharp endpoints for drug susceptibility testing (3). Appropriate biohazard class facilities were used. Each of the broth media used for MIC testing is a completely defined synthetic medium. No single medium will produce optimal control growth for all 15 species tested. However, it was shown in earlier studies that if one medium was chosen to test many * Corresponding author. species, the endpoints determined by using that medium would not be significantly different from those found using media that maximize growth of the organisms being tested (3). Details of methodology are further specified below and in Table 1 . and Cryptococcus neoformans were measured spectrophotometrically; other yeasts were enumerated in a hemacytometer. Mycelial fungi were harvested from solid media and enumerated. All fungi were diluted in the appropriate broth medium and drug dilution so that the final inoculum was 1,000 cells per ml.
ABDS was supplied as a lyophilized powder containing sodium deoxycholate and buffered with sodium phosphate. It was reconstituted with sterile water, stored frozen, and protected from light. ABCD was supplied as a lyophilized powder, reconstituted in sterile water, stored at 4°C protected from light, and used within 1 week. A twofold dilution series of each drug was prepared in medium. Final concentrations in tubes with the inocula ranged from 16 to 0.125 p.g/ml.
Plastic tubes with loose flip caps were used for the MIC determination. The broth volume in each tube was 2 ml. Each dilution series included a tube with medium but no drug. A dilution of the inoculum was placed on solid medium to verify absence of contamination, inoculum quantitation, NOTES To determine the minimum fungicidal concentration (MFC), plates containing appropriate solid media were divided into quadrants. From each dilution series, contents of the tubes without evident growth or with questionable trace growth and of the tube with no drug were vigorously mixed, and 0.04 ml was removed from each tube and placed on a quadrant. The plates were incubated until growth from tubes containing no drug was evident. The MFC was considered the lowest concentration producing one or no colonies on the plate. Tubes with questionable trace growth which produced one or no colonies in the MFC assay necessitated a rare reassessment of the MIC designation; such tubes, which met the criteria for fungicidal activity, were also considered to be at or below the MIC. A known ABDS-susceptible organism was assayed periodically during these experiments to confirm drug potency and assay reproducibility, and the results were always -1 twofold dilution different from that recorded previously in our laboratory.
The results are shown in Table 2 . The range of MICs of ABDS was 0.25 to 4.0 jig/ml, and MICs of ABCD were .0.125 to >16 ,ug/ml. For 31 of 41 isolates, the ABCD MIC was _4 ,ug/ml. For 16 isolates, the ABDS MIC was lower than that of ABCD; for 16, the reverse was true; and for 9, the MICs were identical. In 15 of the 32 instances of differences in MICs, the differences were considered large (fourfold or more), and they appear nonrandom in that in 12 of these 15, the ABDS MIC was lower. Notably, these 12 included 8 (of the 11) Aspergillus isolates. The MFC ranges were 0.25 to >16 and <0.125 to >16 ,jg/ml for ABDS and ABCD, respectively. For 17 isolates, the ABDS MFC was lower than that of ABCD; for 17, the reverse was true; and for 7, the MFCs were identical. In 17 of the instances of discordance, the differences were large, and in 12 of these, the ABDS MFC was lower. Discordances were not reported with liposomal preparations and ABDS (10) .
Organisms for which differences in susceptibility were (8), this could not explain the species differences seen in these studies (Tables 1 and 2 ). Thus, ABCD complexing variably affects AmB in vitro activity compared with that of ABDS. Neither preparation was favored in terms of number of isolates with higher or lower results in either the MIC or MFC assays. In less than a third of comparisons are there large (fourfold or more) decreases in activity with ABCD complexing, and in approximately 10%, there is a large increase. AmB complexed in ABCD apparently is generally able to reach its fungal targets. Some trends between fungal species may have emerged in these studies. Since animals can tolerate larger doses of ABCD than of ABDS and since the organ distribution of the two preparations is different (1, 2, 6 ), the possible significance of these in vitro differences must be addressed in in vivo studies. This is a potentially important issue, since clinical trials with ABCD are beginning.
